Centrum Medyczne Luxmed Sp. z o.o.
- Address
- lock Available on a paid plan
Psychiatry and Psychology – Mental Disorders
The Centrum Medyczny Luxmed site in Lublin concentrates on clinical research in psychiatry and psychology, addressing major mood and psychotic conditions. Current studies evaluate innovative treatments for major depressive disorder, including variants with severe anhedonia, as well as adjunctive strategies for refractory schizophrenia and treatment‑resistant schizophrenia. The primary goal is to determine safety, tolerability, and therapeutic benefit for patients with persistent mental health challenges.
- Major Depressive Disorder (MDD)
- MDD with Moderate‑to‑Severe Anhedonia
- Refractory Schizophrenia
- Treatment‑Resistant Schizophrenia (TRS)
Ongoing trials feature long‑term safety assessments of a kappa‑opioid receptor antagonist, adjunctive agents such as aticaprant and NBI‑1065845 for relapse prevention, and dose‑response investigations of NaBen® combined with clozapine. Another study examines evenamide as an add‑on therapy for patients who do not respond to standard antipsychotics. Together, these efforts aim to broaden therapeutic options and improve outcomes for individuals living with chronic depressive or psychotic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neumora Therapeutics Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Luxmed Sp. z o.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder. | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Mar 2023 | Nov 2025 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine | 2 | Unknown | 2024-07-18 | 2024-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.